Prostate Cancer Coverage from Every Angle

Tanya Dorff, MD, on New Findings on Talazoparib Monotherapy in Prostate Cancer

Posted: Thursday, September 1, 2022

Tanya Dorff, MD, of City of Hope, discusses findings from the TALAPRO-1 study, which explored the use of talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer with tumor DNA damage response alterations. In addition, Dr. Dorff examines the germline alteration landscape and potential associations with antitumor activity.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.